Nuritas Secures €40M to Scale AI-Driven Biotech Solutions
Nuritas, a Dublin-based biotech company that harnesses artificial intelligence (AI) to develop new supplements and drugs, has raised €40 million in a funding round led by M&G Investments. This latest investment brings the total funds raised by Nuritas to more than €100 million. Previously, the company raised €39 million in a Series B round in 2021.
Innovating Health with AI
Founded in 2014 by Dr. Nora Khaldi, Nuritas has quickly gained recognition for its groundbreaking approach to biotechnology. In 2016, U2’s Bono and The Edge joined as backers, highlighting Nuritas’ potential. McWin Capital Partners, a private equity firm focused on high-growth companies in the food sector, also invested in this round. 
M&G Investments led the funding as part of its Catalyst strategy, which targets companies addressing critical global challenges. This capital will enable Nuritas to scale its operations and reach more customers globally.
Revolutionizing Health Products with AI
Nuritas created Magnifier, an AI platform that discovers bioactive peptides—small proteins with significant health benefits. These peptides integrate into food, supplements, skincare products, and other functional ingredients. Nuritas has already commercialized three major products: PeptiStrong, PeptiYouth, and PeptiPump. The company plans to release new products annually, with two slated for launch in 2025.
PeptiYouth, for example, promotes collagen production and reduces wrinkles, and it is already featured in skincare products across the US and Asia. Through these products, Nuritas has formed strong partnerships with global brands such as Givaudan, Nestlé, Mars, and Sumitomo Corporation.
Addressing Global Health Challenges
Dr. Khaldi, CEO of Nuritas, emphasized the company’s mission: “We aim to improve the lives of billions by creating ingredients that solve global health challenges.” She explained that their science-first approach enables customers to develop healthier, more differentiated products that cater to today’s consumers.
Alex Seddon, head of impact and private equity at M&G Investments, and Henry McGovern, co-founder of McWin Capital Partners, will join the Nuritas board as part of this funding round.
Accelerating Growth
Nuritas continues to focus on investing in its technology and business growth. According to its most recent financial reports, the company accumulated €27.9 million in losses by the end of 2022 as it expanded. Despite this, the €40 million in new funding and its growing portfolio of partnerships position Nuritas to further impact the health and wellness market.
In summary, this €40 million funding will allow Nuritas to scale its operations, broaden its customer base, and continue developing innovative AI-driven health solutions that address global needs.
